First-in-human assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the phase 1 PAnTHa study. Visual PSMA-PET and ...
PSMA PET-based (PPP3) nomograms outperform conventional risk scoring in determining overall survival over 3, 5, and 7 years across the prostate cancer spectrum. Nomograms based on prostate-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results